Polprazol PPH

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Polprazol PPH

What is Polprazol PPH? (Overview)

For quick reference, here are the essential details about the nature of this medicine:

Property Description
Active Ingredient Omeprazole
Form Hard capsules with enteric-coated pellets
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Long-term suppression of gastric acid
Origin Synthetic (chemically manufactured)

What Type of Medicine is Polprazol PPH?

Polprazol PPH is a medicine classified as a powerful acid reducer belonging to the pharmacological class known as Proton Pump Inhibitors (PPIs). This class of drugs is recognized for its efficacy in reducing gastric acidity. Omeprazole works by decreasing the amount of acid made in the stomach. This means the medicine is designed to provide sustained suppression of acid secretion, which is key to managing chronic acid-related symptoms.


Omeprazole: The Active Ingredient and Form

The single active ingredient in Polprazol PPH is omeprazole, a synthetic molecule responsible for its therapeutic effect. The product is formulated as hard capsules containing specialized enteric-coated pellets. This specific formulation is critical; without the protective enteric coating, omeprazole would be rapidly degraded by stomach acid. These capsules are gastro-resistant to ensure the active drug is delivered intact to the small intestine where it can be properly absorbed, making the delivery consistent and reliable.


What is the General Purpose of Polprazol PPH?

The fundamental purpose of Polprazol PPH is to consistently and profoundly lower the level of acid within the stomach over a sustained period. By achieving this high degree of acid suppression, the medicine helps to relieve the pain and discomfort associated with excess gastric acidity, such as persistent heartburn. More importantly, this reduction creates the optimal environment for the upper digestive tract lining—including the esophagus and stomach—to heal from any damage or inflammation caused by chronic acid exposure.

Regulatory References

  1. MedlinePlus database

What side effects are possible with Polprazol PPH?

Possible Side Effects and Safety Information

The safety profile for Polprazol PPH (Omeprazole) is structured according to authoritative regulatory classifications, detailing adverse reactions by the body system affected and their frequency of occurrence.

Adverse Reactions by Frequency

Frequency Examples of Documented Adverse Reactions
Common (1 in 10 to 1 in 100) Headache, abdominal pain, constipation, diarrhea, flatulence, nausea/vomiting, benign stomach polyps.
Uncommon (1 in 100 to 1 in 1,000) Insomnia, dizziness, skin rash, itching, malaise, increased liver enzymes, bone fractures (hip, wrist, or spine).
Rare (1 in 1,000 to 1 in 10,000) Severe hypersensitivity reactions (including fever, angioedema, anaphylactic shock), low sodium levels (hyponatraemia), confusion, hepatitis, hair loss, acute kidney inflammation (tubulointerstitial nephritis).
Very Rare (<1 in 10,000) Agranulocytosis (severe reduction in white blood cells), liver failure, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis).
Not Known Low magnesium levels (hypomagnesaemia), microscopic colitis, certain lupus conditions (subacute cutaneous lupus erythematosus).

Important Safety Considerations

Safety constraints and patterns are documented in regulatory labeling.

  • Malignancy Exclusion: Symptom relief with Polprazol PPH does not rule out the presence of gastric malignancy; testing is required before starting treatment.
  • Duration-Related Risks: Long-term use (typically over one year) is associated with an increased risk of bone fractures and vitamin B12 deficiency. Prolonged use may also lead to hypomagnesaemia.
  • Population Specificity: Caution is advised, as encephalopathy has been reported in patients with pre-existing severe liver disease. Monitoring of magnesium levels is often required during long-term therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical manifestations and required emergency actions in the event of an overdose of Polprazol PPH (omeprazole), based strictly on government regulatory documents.

Documented Overdose Manifestations

Official labeling indicates that experience with omeprazole overdose is limited, and symptoms are typically minor and reversible. Documented manifestations may include gastrointestinal distress (nausea, vomiting, diarrhea, abdominal pain), central nervous system effects (headache, confusion, lethargy), and autonomic symptoms such as tachycardia and increased sweating.

Emergency Actions and Supportive Management

Immediate Medical Attention Required

In the event of a suspected overdose, it is an officially mandated action to seek immediate medical attention or contact a Poison Help line right away. Hospital monitoring may be required to manage any potential adverse effects.

Antidote and Treatment

There is no specific antidote known for omeprazole overdose. Treatment must be symptomatic and supportive. Due to the drug's extensive plasma protein binding, regulatory information states that dialysis is not expected to be effective in clearing the substance from the system.

Therapeutic Uses of Polprazol PPH

Quick Facts: Uses of Polprazol PPH

  • Helps manage symptoms related to Gastroesophageal Reflux Disease (GERD).
  • Supports healing of acid-related damage to the esophagus (erosive esophagitis).
  • Aids in treatment of duodenal and gastric ulcers.
  • Used in combination with antibiotics to manage H. pylori infection.
  • Offers treatment for pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Polprazol PPH is a prescription medication utilized in managing conditions associated with excess stomach acid production. The therapeutic application of this drug is centered on reducing the acid level in the stomach, which allows the lining of the digestive tract to heal and helps relieve discomfort.

One primary use is the short-term treatment and maintenance of healing of erosive esophagitis, a condition where stomach acid damages the lining of the esophagus. The medication is also employed to help manage the symptoms of Gastroesophageal Reflux Disease (GERD), which may include heartburn.

Additionally, Polprazol PPH is an option for treating active gastric (stomach) and duodenal (small intestine) ulcers. When ulcers are linked to the presence of the Helicobacter pylori (H. pylori) bacterium, this drug is often prescribed as part of a combination regimen with specific antibiotics to help eradicate the infection. Furthermore, it provides long-term management for conditions where the stomach produces abnormally high amounts of acid, such as Zollinger-Ellison syndrome.

Eligibility and Restrictions for Use

Who Can and Cannot Use Polprazol PPH? (Official Eligibility)

Polprazol PPH (omeprazole) eligibility is strictly defined by government regulatory agencies through contraindications, age limits, and conditional use criteria.


Contraindicated Populations

The medicine must not be used by individuals with:

  • Known hypersensitivity to omeprazole, any component of the formulation, or to substituted benzimidazoles.
  • Concurrent treatment with certain antiretroviral agents, specifically nelfinavir or rilpivirine.

Age-Group and Condition-Specific Eligibility

Population Group Regulatory Status
Adults (age ge 18) Approved for all labeled indications.
Pediatric (age < 1 year) Safety and effectiveness have not been established.
Hepatic Impairment Use requires caution, and a dose reduction should be considered as the drug’s exposure may be increased.
Pregnancy Use is permitted by some authorities, though use should be considered only when the benefit justifies the potential risk.
Breastfeeding Caution is advised due to excretion into breast milk; warnings exist for potential serious adverse effects in the infant.

Regulatory Summary

Official labeling sets clear boundaries for use: absolute non-eligibility is determined by allergies or specific drug interactions. Eligibility is conditioned by age (with a minimum limit of one year) and organ function (hepatic caution). Decisions on use in pregnancy and breastfeeding are based on a formal assessment of the available data, as outlined in official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Polprazol PPH (omeprazole) is governed by its effect on gastric pH and its documented inhibition of the CYP2C19 enzyme.

Interaction-Related Restrictions

Classification Interacting Substances (Examples)
Avoid Combination Clopidogrel, Atazanavir, Nelfinavir, Rilpivirine (antiretrovirals)
Avoid Co-use St John's Wort, Rifampin (enzyme inducers)

Official regulatory documents advise avoiding co-administration with Clopidogrel due to the documented risk of diminished anti-platelet activity. The combination is also not recommended with certain antiretrovirals (e.g., Atazanavir) as omeprazole reduces their plasma levels.

Exposure Modification and Monitoring

Omeprazole prolongs the elimination of drugs metabolized by CYP2C19, such as Warfarin, Phenytoin, and Diazepam, potentially increasing their systemic exposure. This requires mandated monitoring of parameters like INR or drug plasma concentrations. The acid-suppressing effect interferes with the absorption of pH-dependent drugs, including Ketoconazole and Iron salts.

Procedural Constraint

Polprazol PPH use elevates Chromogranin A (CgA) levels. To avoid false positive results in diagnostic investigations for neuroendocrine tumors, regulatory guidelines require that the medicine be temporarily stopped at least 14 days before the CgA assessment.

Mechanism of Action

Irreversible Inhibition of Gastric Acid Secretion

Polprazol PPH operates through a mechanism involving dual component interaction. The primary active component, omeprazole, is a pro-drug that undergoes acid-catalyzed conversion into its active sulfenamide form within the highly acidic secretory canaliculi of the stomach’s parietal cells. This active metabolite then establishes a permanent covalent bond with sulfhydryl groups on the H^+/ K^+-ATPase (Proton Pump) enzyme. This binding results in irreversible, non-competitive inhibition of the enzyme, blocking the final step of hydrogen ion secretion into the gastric lumen and leading to a sustained reduction in gastric acid output.

Mechanistic Synergy and Duration

Sodium bicarbonate, the second component, provides immediate pH buffering in the stomach, which serves to protect the acid-sensitive omeprazole from degradation before its systemic absorption. This component interaction promotes the stability and absorption of the omeprazole component. The duration of the physiological effect is determined by the need for the parietal cell to synthesize new H^+/ K^+-ATPase to restore acid-secreting capacity, a process that requires approximately 24–48 hours.

Dosage and Administration Information

How Polprazol PPH is used: Administration Guidelines

Polprazol PPH is an oral medication, classified as a Delayed-Release Capsule (gastro-resistant), and must be used according to the specific administration instructions.

Administration Details

Feature Guideline
Route of Administration Oral. The capsule must be swallowed whole to preserve the enteric coating.
Timing in Relation to Meals Should be taken before eating, preferably in the morning.
Standard Adult Dosing The typical dose is 20 mg or 40 mg once daily. Initial doses for Pathological Hypersecretory Conditions are 60 mg once daily.
Frequency Rule Primarily once daily administration. Daily dosages greater than 80 mg must be administered in divided doses.
Course Duration Short-term treatment is typically 4 to 8 weeks for acute conditions. Maintenance treatment for healed erosive esophagitis can extend up to 12 months.

Handling and Special Populations

To ensure proper function, the delayed-release capsule must not be crushed or chewed. If a patient cannot swallow the capsule whole, the contents (pellets) may be emptied into a small amount of applesauce and swallowed immediately without chewing the pellets. If a dose is missed, it should be taken as soon as remembered, but if it is near the time of the next dose, the missed dose should be skipped; doses must not be doubled.

Dosage adjustments are generally not needed for older adults or patients with impaired renal function. However, for patients with severe hepatic impairment, a maximum daily dose of 10 mg to 20 mg may be advised. For pediatric patients, dosing is weight-based and determined by a healthcare provider.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Overview of Investigation and Early Research

Research was conducted to understand the compound's characteristics. This initial phase of investigation focused on understanding the biochemical activity in preclinical and laboratory settings.

  • Initial in-vitro experiments examined the compound’s binding affinity.
  • Toxicology studies in animal models were conducted to establish a preliminary safety profile.

Efficacy Findings: Placebo-Controlled Trials

Phase II and III clinical trials were designed to investigate the compound's effect compared to an inactive placebo.

Acute Symptom Assessment

Research examined the compound versus placebo and reported on the time to change in reported acute pain. These studies evaluated endpoints such as the change in pain scores from baseline using the VAS scale.

  • Studies evaluated two dosing levels over a 7-day period. Certain study protocols investigated administration at different times and reported on morning symptoms.
  • Research reported on measures related to the required dosage of rescue medication in study subjects.

Long-term Measures

Clinical trials evaluated one dosing level and reported on patient mobility and measures of pain management over a 6-month period.

  • Findings documented the impact on quality of life questionnaires.
  • Research explored the long-term impact on joint stiffness measurements.

Safety and Tolerability

Adverse events across the placebo-controlled trials were systematically documented.

Key Adverse Events

The most frequently reported adverse events were headache, mild nausea, and fatigue. Analysis documented the proportion of participants who discontinued treatment due to side effects compared to placebo.

Special Populations

Study participants included individuals with mild kidney issues, and the findings were documented. Separate studies have explored the combination with Z-type medication and reported adverse events.


Areas for Further Study

This compound's characteristics were reported by researchers as a focus of the investigation. It is not yet clear whether the long-term influence on disease progression extends beyond the 6-month trial period. Further research is evaluating other potential markers of inflammation.

Key Studies & References

  1. Omeprazole-induced interstitial nephritis (Used for information on kidney issues and documented findings in special populations)

Frequently Asked Questions (FAQ)

Common questions about Polprazol PPH (FAQ)

Q: Is Polprazol PPH the same thing as omeprazole?

Polprazol PPH is the brand name given to this specific medicine formulation. The single active ingredient that performs the acid-reducing action is omeprazole. This ingredient is classified as a Proton Pump Inhibitor (PPI), a group of medicines widely used to reduce gastric acid production.


Q: How long does the effect of Polprazol PPH last after taking a dose?

The mechanism of action involves omeprazole permanently blocking acid-producing pumps in the stomach's cells. This means the acid-reducing effect persists until the body can synthesize new pumps. This process typically requires approximately 24 to 48 hours, contributing to the medicine's sustained effect.


Q: Can I take Polprazol PPH if I also take supplements like iron or magnesium?

Official information indicates that omeprazole can interfere with the body's absorption of certain minerals. Regulatory documents note that omeprazole can reduce the absorption of iron salts. Long-term use is also associated with a documented risk of low magnesium levels (hypomagnesaemia).


Q: What kind of monitoring is typically done when a person is on long-term Polprazol PPH?

Regulatory guidance suggests that when this medicine is used long-term, monitoring of certain laboratory parameters may be necessary. This may include checking magnesium levels due to the risk of deficiency. For patients concurrently taking the blood thinner warfarin, monitoring of the International Normalized Ratio (INR) is required.


Q: Do official documents mention hair loss as a side effect of Polprazol PPH?

Yes, regulatory documents classify hair loss (alopecia) as a documented adverse reaction. This is categorized as a rare effect, meaning it is reported to affect up to 1 in 1,000 people.


Q: Is there a link between Polprazol PPH and vitamin B12 deficiency?

Official regulatory warnings state that long-term use of the medicine, generally defined as over one year, is associated with an increased risk of developing vitamin B12 deficiency. This risk is related to the chronic reduction of stomach acid levels.


Q: Is Polprazol PPH safe for people with liver problems?

Official information advises that use requires caution in patients who have severe hepatic impairment (liver problems). A dose reduction may be considered in these cases, and rare but serious effects like encephalopathy have been reported in this patient group.


Q: What is the difference between Polprazol PPH and over-the-counter stomach acid reducers?

Polprazol PPH typically refers to a prescription-strength medicine. While the active ingredient, omeprazole, is also available at a lower strength for short-term, over-the-counter (OTC) use, the higher strength and the conditions it is approved to treat usually require a prescription.


Q: How quickly does Polprazol PPH usually start to work?

The initial acid-reducing effect is generally described as beginning within one hour of administration, with the strongest effect occurring within two hours. However, achieving the drug's full, sustained therapeutic effect may require 2 to 3 consecutive days of administration.


Q: Can Polprazol PPH be taken long-term?

Treatment courses are generally short-term, typically 4 to 8 weeks for acute conditions. However, the medicine is approved for certain long-term maintenance uses, such as for healed erosive esophagitis, which may extend up to 12 months or longer under medical guidance. Official documents caution that long-term use is associated with certain documented risks.


Q: What happens if I stop taking Polprazol PPH suddenly?

While official labeling does not usually address discontinuation, regulatory-backed clinical reviews describe a pattern observed after stopping a PPI. Some patients may experience a temporary increase in stomach acid production, which can cause symptoms to return for a period.


Q: Can Polprazol PPH cause changes in mood or anxiety?

Official documents list some psychological effects as possible adverse reactions. Confusion and insomnia (difficulty sleeping) are listed as uncommon reactions. Agitation and depression are documented as rare adverse reactions.


Q: Is it normal to have a headache when first starting Polprazol PPH?

Official documents classify headache as a common adverse reaction, meaning it is among the most frequently reported side effects. The official information does not, however, specify whether this reaction occurs only when first starting therapy.


Q: Does Polprazol PPH affect the absorption of any other medicines?

Yes, this medicine can affect other drugs in two primary ways. By reducing stomach acid, it interferes with the absorption of pH-dependent drugs (like ketoconazole). It also affects a liver enzyme (CYP2C19), which can prolong the elimination of certain drugs, such as warfarin.


Q: Why is Polprazol PPH sometimes prescribed for H. pylori infection?

The medicine is approved as a part of combination therapy to treat H. pylori infection. This use is intended to increase the stomach's pH level, a change in acidity that is thought to create an environment that supports the activity of the antibiotics used in the combination.


Q: Can Polprazol PPH cause stomach pain or upset?

Yes, official regulatory documents list abdominal pain as a common side effect. Nausea and vomiting are also listed as common adverse reactions that can occur with the use of this medicine.


Q: Does Polprazol PPH affect kidney function over time?

The development of acute tubulointerstitial nephritis, which is a type of acute kidney inflammation, is documented as a rare adverse reaction. Official reports indicate this reaction can occur at any point during treatment.


Q: Is there a maximum time that Polprazol PPH can be used?

For certain conditions requiring prescription use, the labeled duration may be up to 12 months for maintenance therapy. For the over-the-counter version of omeprazole, regulatory guidelines limit use to 14 days without further consultation.


Q: Are generic versions of Polprazol PPH available?

Yes, since Polprazol PPH contains the active ingredient omeprazole, numerous generic and biosimilar versions of omeprazole have been approved by regulatory agencies worldwide. These products contain the same active ingredient and meet the same quality standards as the brand-name medicine.


Q: Is it true that Polprazol PPH is used to prevent ulcers in certain patients?

Yes, official indications include the risk reduction of gastric ulcers. Specifically, it is approved for patients who have a history of developing ulcers and are continuing to take Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Q: Do studies show a connection between Polprazol PPH and bone density?

Official regulatory warnings highlight an increased risk of bone fractures of the hip, wrist, or spine in patients on high doses or those taking the medicine for a long time. This risk is attributed in part to reduced calcium absorption resulting from low stomach acid.


Q: Can I take an antacid like Tums while I am taking Polprazol PPH?

Regulatory-backed patient information generally suggests that antacids can be used as needed for symptom relief while taking a PPI. Guidance generally suggests that the antacid not be taken at the exact same moment as the delayed-release capsule, which helps ensure the capsule's protective coating remains intact.


Q: How does Polprazol PPH compare to H2 blockers in regulatory descriptions?

Official comparative descriptions generally describe omeprazole (a PPI) as a more potent and longer-acting acid suppressor compared to H2 blockers. While H2 blockers may start working faster, the effects of PPIs are often more sustained and generally more effective for healing severe inflammation.


Q: Is it common to have gas or bloating when taking Polprazol PPH?

Yes, flatulence (gas) is classified as a common adverse reaction in official documents, meaning it may affect up to 1 in 10 people. Abdominal pain is also listed as a common side effect.


Q: Are there specific patient groups that should use caution with Polprazol PPH?

Official warnings advise caution for several groups. Groups for whom caution is advised include patients with severe liver disease and those who may have pre-existing low magnesium levels. Caution is also advised when co-administering the medicine with certain drugs, such as Clopidogrel or specific antiretroviral medications.


Q: What is the overall safety profile of Polprazol PPH described in official documents?

Official documents describe the medicine as generally well-tolerated. The majority of reported adverse reactions are common and mild, such as headache and nausea. Serious adverse reactions (like severe allergies or kidney inflammation) are documented as rare events.


Q: How is the long-term effectiveness of Polprazol PPH described in studies?

Clinical trials support the effectiveness of omeprazole for the long-term maintenance of healing for certain conditions, such as erosive esophagitis. The duration of controlled long-term studies extends up to 12 months, demonstrating sustained effectiveness in maintaining the health of the digestive lining.


Q: What happens if Polprazol PPH is taken for a short period of time?

The medicine is approved for short-term treatment, typically lasting 4 to 8 weeks. This duration is used for acute conditions, including the healing of active duodenal ulcers, gastric ulcers, and erosive esophagitis.


Q: What is the primary mechanism described for how Polprazol PPH reduces acid?

The medicine reduces acid by irreversibly blocking the Proton Pump enzyme (specifically the H^+/ K^+-ATPase) located in the stomach's parietal cells. This action blocks the final step in the production of gastric acid.


Q: Is Polprazol PPH effective for nighttime heartburn?

Omeprazole, the active ingredient, is a powerful acid reducer. However, some clinical reviews note that the standard delayed-release form may not fully suppress nocturnal acid breakthrough. A different, immediate-release formulation of omeprazole is available that is specifically approved for use to address nighttime symptoms.


Q: Is Polprazol PPH a prescription-only medicine?

The active ingredient, omeprazole, is available in different regulatory classifications. Depending on the strength and the specific product formulation, it is sold in both prescription-only (Rx) strengths and lower, over-the-counter (OTC) strengths.

How should Polprazol PPH be stored and disposed of?

Polprazol PPH capsules must be stored under specific conditions to maintain their stability, as documented in regulatory labeling.

Storage Requirements

Requirement Condition
Temperature Do not store above 30degree C (86degree F) [source 1.2].
Environmental Protection Protect from moisture and light [source 1.4].
Packaging Rule Store in the original package (blister) or keep the container tightly closed (bottle) [source 1.2].
In-Use Stability For HDPE bottles, the product is stable for 100 days after first opening [source 3.1].
Child Safety Keep out of the sight and reach of children [source 2.3].

Disposal

When the medicine is no longer needed, it must be disposed of in accordance with local pharmaceutical waste requirements [source 1.2]. Do not dispose of the capsules via household trash or wastewater unless the labeling specifically directs it [source 2.2].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Polprazol PPH found in:

A-Z Index: